Achieve Life Sciences Inc., of Bothell, Wash., said it initiated the development program for its smoking cessation candidate, cytisine, a plant-based alkaloid with a high binding affinity to the nicotinic acetylcholine receptor that is approved and marketed in Central and Eastern Europe.